Form 4: Century Therapeutics Insider Sells Shares

Chad Cowan, Chief Scientific Officer at Century Therapeutics, reported a transaction involving the sale of common stock.

Summary

• Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc., reported a transaction on April 1, 2026.
• The transaction involved the withholding of 1,365 shares of common stock by the Issuer to satisfy tax obligations related to the vesting of restricted stock units.
• Following this transaction, Mr. Cowan directly beneficially owns 1,175,680 shares of common stock.
• Additionally, 10,697 shares are held indirectly by the Cowan Investment Nominee Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard insider transaction for tax withholding purposes rather than a strategic decision to buy or sell shares based on company performance.

Negatives

• Insider selling can sometimes be interpreted negatively by the market, although in this case, it was for tax withholding purposes.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The specific details of this transaction, involving tax withholding for vested RSUs, are common occurrences for executives and do not inherently signal a change in the company's strategic direction or financial health.

Stakeholder Impact

• Shareholders: The transaction is a routine tax event for the executive and is not expected to have a significant direct impact on the share price or company operations.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership